NCT02524717View on ClinicalTrials.gov

A Study to Evaluate the Pharmacokinetics of JNJ-56021927 in Participants With Mild or Moderate Hepatic Impairment Compared With Participants With Normal Hepatic Function

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

August 13, 2015

Primary Completion Date

February 9, 2017

Study Completion Date

February 9, 2017

Conditions
Hepatic Impairment
Interventions
DRUG

JNJ-56021927

Participants will receive JNJ-56021927 240 milligram (mg) orally once on Day 1.

Trial Locations (2)

Unknown

Knoxville

San Antonio

Sponsors
All Listed Sponsors
lead

Aragon Pharmaceuticals, Inc.

INDUSTRY